(PGNY) Progyny - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74340E1038
PGNY: Fertility, Pharmacy, Adoption, Surrogacy, Doula, Travel
Progyny, Inc. (NASDAQ:PGNY) operates at the intersection of healthcare and benefits management, focusing exclusively on fertility and family-building solutions. The company has carved out a niche by offering a comprehensive suite of services designed to simplify and streamline the complex process of fertility treatments and family planning. Its core solution combines a differentiated benefits plan design with personalized, concierge-style support services, ensuring that members receive tailored guidance throughout their journey. This high-touch approach is complemented by a selective network of fertility specialists, carefully vetted to ensure quality and alignment with Progynys standards.
Progynys offerings extend beyond fertility treatments. The company provides an integrated pharmacy benefits solution, Progyny Rx, which ensures members have seamless access to the medications required during their treatment. This end-to-end approach addresses a critical pain point in fertility care, where timely access to medications can significantly impact outcomes. Additionally, Progyny offers a range of assistance programs, including reimbursement services for adoption, surrogacy, doula support, and travel expenses related to medical treatments. These programs underscore the companys commitment to supporting the diverse needs of families navigating the complexities of building their families.
Founded in 2008 under the name Auxogyn, Inc., the company rebranded as Progyny, Inc. in 2015, signaling its expanded focus and commitment to innovation in the fertility benefits space. Headquartered in New York, New York, Progyny has established itself as a leader in a growing market, with a market capitalization of approximately $1.9 billion as of recent data. The companys financial profile includes a trailing P/E ratio of 36.64 and a forward P/E of 14.25, reflecting investor expectations of future growth. With a price-to-book ratio of 4.38 and a price-to-sales ratio of 1.67, Progynys valuation metrics suggest a balance between growth potential and operational efficiency.
For investors and fund managers, Progynys unique position in the fertility and family-building benefits market presents an interesting opportunity. The companys ability to combine technology, personalized service, and a deep understanding of the fertility landscape sets it apart from competitors. As the conversation around fertility and family-building benefits continues to evolve, Progyny is well-positioned to capitalize on growing demand from employers seeking to offer comprehensive and inclusive benefits packages. The companys focus on improving outcomes, reducing costs, and enhancing the overall experience for its members aligns with broader trends in healthcare and employee benefits.
Additional Sources for PGNY Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PGNY Stock Overview
Market Cap in USD | 1,777m |
Sector | Healthcare |
Industry | Healthcare Plans |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2019-10-25 |
PGNY Stock Ratings
Growth 5y | -23.8% |
Fundamental | 31.2% |
Dividend | 0.0% |
Rel. Strength Industry | -43 |
Analysts | 3.6/5 |
Fair Price Momentum | 18.81 USD |
Fair Price DCF | 27.59 USD |
PGNY Dividends
No Dividends PaidPGNY Growth Ratios
Growth Correlation 3m | 62.8% |
Growth Correlation 12m | -74.6% |
Growth Correlation 5y | -33.2% |
CAGR 5y | 0.77% |
CAGR/Max DD 5y | 0.01 |
Sharpe Ratio 12m | 0.58 |
Alpha | -53.76 |
Beta | 1.09 |
Volatility | 50.49% |
Current Volume | 1612.8k |
Average Volume 20d | 1761.5k |
As of March 15, 2025, the stock is trading at USD 20.36 with a total of 1,612,785 shares traded.
Over the past week, the price has changed by -2.12%, over one month by -8.94%, over three months by +36.74% and over the past year by -42.49%.
Neither. Based on ValueRay Fundamental Analyses, Progyny is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 31.19 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PGNY as of March 2025 is 18.81. This means that PGNY is currently overvalued and has a potential downside of -7.61%.
Progyny has received a consensus analysts rating of 3.60. Therefor, it is recommend to hold PGNY.
- Strong Buy: 3
- Buy: 0
- Hold: 7
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, PGNY Progyny will be worth about 21 in March 2026. The stock is currently trading at 20.36. This means that the stock has a potential upside of +3.29%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 27 | 32.6% |
Analysts Target Price | 18.9 | -7.4% |
ValueRay Target Price | 21 | 3.3% |